Risankizumab-rzaa

Class: Skin and Mucous Membrane Agents, Miscellaneous
Molecular Formula: C₆₄₇₆H₉₉₉₂N₁₇₂₀O₂₀₁₆S₄₄
CAS Number: 1612838-76-2
Brands: Skyrizi ([Web])

Medically reviewed by Drugs.com on Apr 27, 2022. Written by ASHP.

Introduction

Inhibitor of interleukin-23 (IL-23); a recombinant humanized IgG₁ monoclonal antibody that binds specifically to the p19 subunit of IL-23.

Uses for Risankizumab-rzaa

Plaque Psoriasis

Management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Guidelines generally support use of IL-23 inhibitors as monotherapy for moderate to severe psoriasis.

Recommendations for use and selection of psoriasis therapies vary based on patient age, disease characteristics (e.g., severity, location, presence of psoriatic arthritis), and comorbidities (e.g., inflammatory bowel disease).

Psoriatic Arthritis

Used for the management of active psoriatic arthritis in adults. May be used alone or in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs).

The American College of Rheumatology and the National Psoriasis Foundation issued a joint guideline for the treatment of psoriatic arthritis in 2018. Risankizumab is not included in these guidelines; however, current evidence suggests that the drug may provide an additional therapeutic option for patients in whom standard therapies are inadequate.

Recommendations for use and selection of disease-modifying therapies in psoriatic arthritis vary based on the presence of certain disease characteristics (e.g., psoriatic spondylitis/axial disease, enthesitis) and comorbidities (e.g., inflammatory bowel disease, diabetes).

Risankizumab-rzaa Dosage and Administration

General

Pretreatment Screening

• Evaluate patients for tuberculosis prior to initiation of risankizumab therapy.

• Administer all age-appropriate vaccines recommended by current immunization guidelines prior to initiation of risankizumab therapy.

Administration

Sub-Q Administration

Available as single-use prefilled syringes (containing 75 mg/0.83 mL or 150 mg/mL) and injection pens (containing 150 mg/mL). Should appear as a clear to slightly opalescent, colorless to yellow or slightly yellow (depending on concentration) solution; may contain a few translucent to white particles but should not contain large particulates.

Allow prefilled syringe or injection pen to sit at room temperature inside the carton out of direct sunlight for 15–30 minutes (prefilled syringe) or 30–90 minutes (injection pen) prior to administration.

Do not shake the injection.

Administer by sub-Q injection into the upper outer arm, anterior thigh, or abdomen; do not make abdominal injections within 2 inches of the navel. Use thigh or abdomen for self-administration; may use upper arm if administered by a caregiver or clinician. Do not make injections into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.